Bristol-Myers Squibb: all 2,184 studies

Page 16 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In DenmarkCompletedNCT02591732
• A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)WithdrawnNCT02588625Phase 2
• Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU CountriesCompletedNCT02581644
• Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe SepsisTerminatedNCT02576457Phase 1
• A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in KoreaCompletedNCT02556905
• A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)WithdrawnNCT02556086Phase 2
• Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical PracticeCompletedNCT02555839
• Treatment of Pancreatic Cancer With AbraxaneCompletedNCT02555813
• Abraxane in Treatment of Metastatic Breast CancerCompletedNCT02555696
• A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3WithdrawnNCT02551861Phase 2
• ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid TumorsCompletedNCT02551185Phase 1
• Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMSCompletedNCT02546817
• Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter StudyCompletedNCT02546791
• A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the BodyCompletedNCT02538874Phase 1
• HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid TumorsCompletedNCT02536469Phase 1
• Safety Study of BMS-986165 in Healthy Subjects and to Treat PsoriasisCompletedNCT02534636Phase 1
• Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsCompletedNCT02534506Phase 1
• Impact of Hyperbilirubinemia Among HIV Patients Treated With AtazanavirCompletedNCT02532673
• Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization PeriodCompletedNCT02531269
• An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.CompletedNCT02528838
• Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral SuspensionCompletedNCT02521714Phase 1
• A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid TumorsCompletedNCT02516527Phase 1
• Safety and PK Study of CC-90001 in Subjects With Pulmonary FibrosisCompletedNCT02510937Phase 1
• Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type PsoriasisTerminatedNCT02502188Phase 1
• Safety Profile of Nulojix in Home Infusion SettingsCompletedNCT02500498
• A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionCompletedNCT02496078Phase 3
• Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in SwedenCompletedNCT02492828
• PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced MelanomaCompletedNCT02492815
• Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2CompletedNCT02488421
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy VolunteersCompletedNCT02480296Phase 1
• Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenNo longer availableNCT02475382
• Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy PatientsCompletedNCT02456844Phase 1
• A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.CompletedNCT02450877Phase 2
• Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT02447666Phase 2
• Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)CompletedNCT02447341
• Radiolabeled Study of AG-221 in Healthy Male Subjects.CompletedNCT02443168Phase 1
• CV004-007 Thrombosis Chamber StudyCompletedNCT02439190Phase 1
• Relative Bioavailability Study of CC-292CompletedNCT02433457Phase 1
• Cost of Monitoring Patients Treated With Vitamin K Antagonists in SpainCompletedNCT02427516
• Risk of CV Events With EFV vs. EFV-free RegimensCompletedNCT02426866
• A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.CompletedNCT02417285Phase 1
• Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line MonochemotherapyCompletedNCT02403869
• Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in TaiwanCompletedNCT02402699
• Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple MyelomaTerminatedNCT02400242Phase 1
• Post-authorisation Study of Biological Relapse in Patients With Multiple MyelomaTerminatedNCT02394210
• Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry StudyCompletedNCT02389972
• A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TRStatus unknownNCT02387879
• PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian SubjectsCompletedNCT02387866Phase 1
• Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)CompletedNCT02368522
• Expanded Access Treatment Protocol CA204-143No longer availableNCT02368301
• A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic CancersCompletedNCT02367196Phase 1
• A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's DiseaseCompletedNCT02367183Phase 1
• Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare PopulationCompletedNCT02363868
• Single Ascending Dose Study of MYK-461 in Healthy VolunteersCompletedNCT02356289Phase 1
• An Observational Study of the Functional Capacity of Heart FailureCompletedNCT02350114Not applicable
• Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Phase 2
• Factors Associated With Biologic DMARD SwitchingCompletedNCT02346942
• Early Post-Marketing Study of ELIQUIS (Apixaban) in MexicoCompletedNCT02345343
• A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCompletedNCT02343536Phase 1
• Observational Study of Quality of Live in Patients With Metastatic Pancreatic CancerCompletedNCT02342847
• Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib TreatmentCompletedNCT02341781
• Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy SubjectsCompletedNCT02341638Phase 1
• Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) CountriesCompletedNCT02339818
• Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in TaiwanCompletedNCT02335606
• Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461CompletedNCT02329184Phase 1
• Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy SubjectsCompletedNCT02327273Phase 1
• Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver CancerTerminatedNCT02323906Phase 1
• A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and AsunaprevirCompletedNCT02323594Phase 1
• Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect StudyCompletedNCT02321644Phase 1
• Safety and PK Study of CC-90003 in Relapsed/Refractory Solid TumorsTerminatedNCT02313012Phase 1
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerCompletedNCT02309177Phase 1
• Taste Properties of Atazanavir and CobicistatCompletedNCT02307656Phase 1
• A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy SubjectsCompletedNCT02293629Phase 1
• Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)CompletedNCT02286219Phase 1
• Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)CompletedNCT02279654
• Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic HyperbilirubinemiaTerminatedNCT02267707Phase 1
• Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy SubjectsCompletedNCT02262533Phase 1
• Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy SubjectsCompletedNCT02262520Phase 1
• Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy SubjectsCompletedNCT02257151Phase 1
• A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCompletedNCT02252263Phase 1
• Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis CCompletedNCT02250001
• Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific GenesCompletedNCT02236195Phase 2
• Radiolabeled Study of CC-122 in Healthy SubjectsCompletedNCT02234999Phase 1
• Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)CompletedNCT02227459Phase 1
• A Phase 1 Drug-drug Interaction Study in Healthy VolunteersCompletedNCT02227173Phase 1
• YERVOY® Risk Minimization Tool Effectiveness Evaluation SurveyCompletedNCT02224768
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Phase 1/1b Study of MGCD516 in Patients With Advanced CancerCompletedNCT02219711Phase 1
• Suicidality and Suicide Attempt Among HIV Patients on Efavirenz-containing Versus Efavirenz-free Antiretroviral RegimensCompletedNCT02211807
• A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male SubjectsCompletedNCT02211469Phase 1
• Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120CompletedNCT02208882Phase 1
• A Phase 2 Study With CC-220 in Skin SarcoidosisWithdrawnNCT02192489Phase 2
• Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple MyelomaCompletedNCT02189343Phase 1
• Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaNo longer availableNCT02186249
• Study of Drug Combination on Pharmacokinetics in Healthy VolunteersCompletedNCT02175602Phase 1
• Post-marketing Study Assessing the Long-Term Safety of AbataceptCompletedNCT02169544
• Food Effect and CYP1A2 Induction Study in Healthy SubjectsCompletedNCT02168205Phase 1
• A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.CompletedNCT02164955
• Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy SubjectsCompletedNCT02164812Phase 1
• Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological MalignanciesCompletedNCT02164071

← Bristol-Myers Squibb overview and focus areas